If you’re trying to place a biomanufacturing facility heading into 2026, the issue isn’t whether the sector is growing. It’s whether your project fits the version of the market that actually exists now.

The last cycle — roughly 2020 through early 2023 — was defined by speed. Capital was abundant, timelines compressed, and capacity was added aggressively across both lab and manufacturing footprints. That cycle has ended. Not because demand disappeared, but because the assumptions behind that expansion have been tested.

Across the major brokerage outlooks, the signal is consistent: biomanufacturing demand remains intact, but capital is tighter, space is more available, and decisions are more disciplined. CBRE’s life sciences research points to a market still working through excess capacity in certain segments, particularly in early-stage lab and flex space, while more specialized manufacturing assets continue to see targeted demand (CBRE). Vacancy has risen from cycle lows, but the increase is uneven — concentrated in generalized space rather than purpose-built facilities.

That distinction matters. The market isn’t oversupplied in a uniform way. It’s misaligned.

JLL’s life sciences outlook reinforces this split, noting that while venture funding and early-stage activity slowed significantly from peak levels, larger pharmaceutical and established biotech companies continue to invest — particularly in advanced manufacturing capabilities and supply chain resilience (JLL). The result is a bifurcated market where speculative development has pulled back, but strategic, long-term projects are still moving forward.

Cushman & Wakefield frames the current moment as a recalibration rather than a contraction. In its life sciences updates, the firm highlights a shift toward efficiency, utilization, and right-sizing, as companies reassess portfolios built during the expansion phase (Cushman & Wakefield). That includes consolidating space, delaying new starts, and prioritizing assets that can support scaled production rather than early-stage experimentation.

For biomanufacturing specifically, that means the bar is higher.

Facilities are more expensive to build, more complex to operate, and more dependent on specialized infrastructure than traditional industrial space. As capital becomes more selective, projects need to demonstrate not just feasibility, but long-term alignment with production needs, regulatory pathways, and workforce availability.

Newmark’s life sciences perspective underscores that capital markets are playing a larger role in shaping what gets built. With higher interest rates and more scrutiny from investors, developers and occupiers alike are favoring build-to-suit and phased development strategies over speculative construction (Newmark). That shift mirrors what’s happening in industrial, but with higher stakes given the cost and specialization involved.

At the same time, geography is becoming more nuanced.

Colliers’ life sciences research continues to highlight the dominance of established clusters — Boston/Cambridge, the San Francisco Bay Area, and San Diego — but also points to the emergence of secondary markets that can offer lower costs, available space, and targeted workforce pipelines (Colliers). The difference from the last cycle is that expansion into these markets is more measured. Companies are not chasing growth for its own sake; they are matching location decisions to specific operational needs.

That’s particularly relevant for manufacturing.

• Reliable utilities and process infrastructure
• Access to specialized technical talent
• Regulatory and permitting clarity
• Proximity to supply chain inputs and distribution networks

Markets that can deliver those elements with certainty are still competitive. Those that cannot are finding it harder to attract projects, even if they were active participants in the last expansion cycle.

Another shift showing up across the reports is timeline pressure.

Where the previous cycle emphasized speed to construction, the current environment emphasizes certainty of delivery. Delays tied to permitting, utilities, or workforce constraints carry greater risk when capital is more constrained and project economics are tighter.

• Site readiness
• Infrastructure commitments
• Workforce development alignment

All of which ties directly back to how biomanufacturing projects are now evaluated.

• Can this market support growth?

• Can this market support this type of production, at this scale, on this timeline?

That specificity is new — or at least newly enforced.

For corporate real estate and site selection teams, the implication is that fewer projects will move forward, but those that do will be more durable. The era of broadly defined expansion has given way to targeted investment aligned with product pipelines and manufacturing strategy.

Biomanufacturing isn’t slowing. It’s filtering.

And in that process, the gap between markets that can support advanced production and those that cannot is becoming much more visible.